Sign In
Buy LPCN
$2.12
+0.0100 (+0.474%)
At Close: Jul 31, 2026
Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis
08:00am, Thursday, 28'th Mar 2024
Met primary and Hepatic Encephalopathy (HE) endpoints in Phase 2 study Increase in Skeletal Muscle Index (SMI) observed at Week 24 was maintained through 52 weeks Participants on placebo increased S
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
08:00am, Monday, 25'th Mar 2024
Company anticipates topline results from this crossover pivotal study late in the second quarter of 2024 SALT LAKE CITY , March 25, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutic
Lipocine Announces Financial Results for the Full Year Ended December 31, 2023
08:00am, Thursday, 07'th Mar 2024
SALT LAKE CITY , March 7, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System ("CNS") disorders, today announced financial results
Lipocine to Present at 36th Annual Roth Conference
08:00am, Wednesday, 06'th Mar 2024
SALT LAKE CITY , March 6, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that Dr. Mahesh V.
Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154
08:00am, Tuesday, 06'th Feb 2024
Positive clinical study results confirm 48-hour dosing regimen for the pivotal PK study On track for Q2-24 pivotal study topline results and planned Q4-24 NDA filing SALT LAKE CITY , Feb. 6, 2024 /P
Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals
08:00am, Friday, 02'nd Feb 2024
SALT LAKE CITY , Feb. 2, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that commercializati
Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada
08:00am, Thursday, 18'th Jan 2024
Lipocine to receive $11 million license fee Up to $259 million in development and commercial sales milestones Tiered royalties on net sales of licensed products up to 18% Commercialization of TLANDO t
Lipocine to Present at Biotech Showcase 2024
08:00am, Tuesday, 19'th Dec 2023
Company Management Will Also Host Meetings at LifeSci Partners Corporate Access Event SALT LAKE CITY , Dec. 19, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused o
Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023
02:45pm, Monday, 13'th Nov 2023
Results demonstrate improvements in sarcopenia and other clinically meaningful outcomes Patients converting from placebo to LPCN 1148 in the ongoing open label extension also showed improvement in sar
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023
08:00am, Wednesday, 08'th Nov 2023
SALT LAKE CITY , Nov. 8, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platfor
Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023
08:00am, Wednesday, 01'st Nov 2023
"Late Breaking" abstract scheduled for oral presentation on November 13 SALT LAKE CITY , Nov. 1, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Cent
Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression
08:00am, Thursday, 26'th Oct 2023
Lipocine and FDA agreed on the acceptance criteria for the pivotal study which enables advancement of LPCN 1154 for postpartum depression (PPD) Company on track to initiate dosing in the pivotal study
Lipocine to Present at the H.C. Wainwright Annual NASH Investor Conference
07:00pm, Monday, 23'rd Oct 2023
SALT LAKE CITY , Oct. 23, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that it will presen
Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference
04:05pm, Tuesday, 19'th Sep 2023
SALT LAKE CITY , Sept. 19, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that Dr. Mahesh P
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023
08:00am, Thursday, 10'th Aug 2023
SALT LAKE CITY , Aug. 10, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced financial results f
